![](/images/graphics-bg.png)
Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial
Joint Authors
Pepin, Jean Louis
Joyeux-Faure, Marie
Tamisier, Renaud
Baguet, Jean-Philippe
Dias-Domingos, Sonia
Perrig, Stephen
Leftheriotis, Georges
Trzepizur, Wojciech
Launois, Sandrine H.
Stanke-Labesque, Françoise
Lévy, Patrick A.
Gagnadoux, Frédéric
Janssens, Jean-Paul
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-08-25
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Rationale.
Accumulated evidence implicates sympathetic activation as inducing oxidative stress and systemic inflammation, which in turn lead to hypertension, endothelial dysfunction, and atherosclerosis in obstructive sleep apnea (OSA).
Statins through their pleiotropic properties may modify inflammation, lipid profile, and cardiovascular outcomes in OSA.
Methods.
This multicenter, randomized, double-blind study compared the effects of atorvastatin 40 mg/day versus placebo over 12 weeks on endothelial function (the primary endpoint) measured by peripheral arterial tone (PAT).
Secondary endpoints included office blood pressure (BP), early carotid atherosclerosis, arterial stiffness measured by pulse wave velocity (PWV), and metabolic parameters.
Results.
51 severe OSA patients were randomized.
Key demographics for the study population were age 54 ± 11 years, 21.6% female, and BMI 28.5 ± 4.5 kg/m2.
In intention to treat analysis, mean PAT difference between atorvastatin and placebo groups was 0.008 (−0.29; 0.28), P = 0.979 .
Total and LDL cholesterol significantly improved with atorvastatin.
Systolic BP significantly decreased with atorvastatin (mean difference: −6.34 mmHg (−12.68; −0.01), P = 0.050 ) whereas carotid atherosclerosis and PWV were unchanged compared to the placebo group.
Conclusion.
In OSA patients, 3 months of atorvastatin neither improved endothelial function nor reduced early signs of atherosclerosis although it lowered blood pressure and improved lipid profile.
This trial is registered with NCT00669695.
American Psychological Association (APA)
Joyeux-Faure, Marie& Tamisier, Renaud& Baguet, Jean-Philippe& Dias-Domingos, Sonia& Perrig, Stephen& Leftheriotis, Georges…[et al.]. 2014. Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial. Mediators of Inflammation،Vol. 2014, no. 2014, pp.1-10.
https://search.emarefa.net/detail/BIM-1043552
Modern Language Association (MLA)
Joyeux-Faure, Marie…[et al.]. Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial. Mediators of Inflammation No. 2014 (2014), pp.1-10.
https://search.emarefa.net/detail/BIM-1043552
American Medical Association (AMA)
Joyeux-Faure, Marie& Tamisier, Renaud& Baguet, Jean-Philippe& Dias-Domingos, Sonia& Perrig, Stephen& Leftheriotis, Georges…[et al.]. Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial. Mediators of Inflammation. 2014. Vol. 2014, no. 2014, pp.1-10.
https://search.emarefa.net/detail/BIM-1043552
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1043552